Deans' stroke musings: Plant-Derived Nanovesicles for Ischemic Stroke Therapy via the Gut Microbiota-Gut-Brain Axis: A New Paradigm of Systemic Regulation

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, May 8, 2026

Plant-Derived Nanovesicles for Ischemic Stroke Therapy via the Gut Microbiota-Gut-Brain Axis: A New Paradigm of Systemic Regulation

I'm hoping there are two working neurons in all of stroke we can rub together to figure out how to use this for stroke recovery along with the previous research.

Nanovesicles (2 posts to November 2021)

Plant-Derived Nanovesicles for Ischemic Stroke Therapy via the Gut Microbiota-Gut-Brain Axis: A New Paradigm of Systemic Regulation

Authors Jiang J , Yu F, He M, Huang R, He H, Murong Z, Xiong S, Liu M

Received 19 January 2026

Accepted for publication 23 April 2026

Published 6 May 2026 Volume 2026:21 597334

DOI https://doi.org/10.2147/IJN.S597334

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Lijie Grace Zhang

Jia Jiang,^1,^* Fang Yu,^2,^* Menghao He,¹ Ruoxuan Huang,³ Haolong He,¹ Zhimiao Murong,³ Shulin Xiong,¹ Mi Liu^1,³

¹Department of Acupuncture, Moxibustion, Tuina and Rehabilitation, The Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People’s Republic of China; ²School of Traditional Chinese Medicine, Hunan University of Medicine, Huaihua, Hunan, People’s Republic of China; ³College of Acupuncture, Moxibustion, Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha, Hunan, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Mi Liu, Email newmean@hnucm.edu.cn Shulin Xiong, Email 241160064@qq.com

Abstract: Ischemic stroke (IS) is a globally significant disease with complex pathological mechanisms. Traditional therapeutic strategies centered on central nervous system-targeted delivery face substantial limitations due to the presence of the blood-brain barrier (BBB) and the multifactorial nature of the disease. In recent years, the gut microbiota-gut-brain axis, which elucidates the multi-pathway dialogue between the gut and the brain, has provided a novel systemic intervention perspective for IS treatment. In this context, Plant-Derived Nanovesicles (PDNVs), a class of natural nanocarriers derived from plants, have emerged prominently due to their inherent multi-component synergistic properties, excellent biocompatibility, and cross-kingdom regulatory capabilities. Critically, IS itself rapidly induces gut dysbiosis and barrier disruption, creating a vicious cycle that amplifies neuroinflammation—a pathological feature shared with other inflammatory conditions such as colitis and Inflammatory bowel disease. In this context, PDNVs, a class of natural nanocarriers derived from plants, have emerged prominently due to their inherent multi-component synergistic properties, excellent biocompatibility, and cross-kingdom regulatory capabilities. Drawing on mechanistic insights from these related disease models, this article systematically discusses the multi-level integrated mechanism of PDNVs as novel “functional messengers”, involving reshaping the gut microenvironment, mediating systemic metabolic-immune signals, and ultimately synergistically activating the central nervous repair network, thereby offering a new paradigm for IS therapy. This review not only summarizes the mechanisms of action of PDNVs but also systematically constructs a framework and strategy for their translation from experimental research to clinical application. Highlighting critical hurdles such as the need for standardized production and rigorous quality control to ensure batch-to-batch consistency. Diagram: stroke impacts brain-gut axis, therapy limits, plant nanovesicles aid gut balance.The diagram illustrates the impact of ischemic stroke on the brain-gut axis and potential therapeutic interventions. It begins with the brain experiencing an ischemic stroke, leading to stroke-associated intestinal injury and a leaky gut. Bidirectional communication is shown between the brain and gut. Therapeutic bottlenecks are highlighted, indicating challenges in treatment. Intact plant-derived nanovesicles are shown being orally administered, maintaining remarkable stability in the stomach. These nanovesicles cross the blood-brain barrier and produce beneficial metabolites, promoting gut homeostasis. The neurovascular unit is depicted as being repaired through these interventions.